Progress map
Age Reversal Progress Map
How many small wins across aging biology may be adding up
Age reversal is not one switch. It is a battlefield of small, uneven advances across metabolism, immune aging, tissue repair, cognition, regeneration, and measurement.
Age Reversal evidence lanes
Epigenetic drift
Early human evidence / score 15
0 studies / 5 sources / 14 briefs / 0 articles
Cellular senescence
Proof of concept / score 41
2 studies / 2 sources / 0 briefs / 2 articles
Mitochondrial function
Early human evidence / score 65
6 studies / 7 sources / 0 briefs / 5 articles
Proteostasis and autophagy
Foundational science / score 53
11 studies / 11 sources / 0 briefs / 6 articles
Nutrient sensing and metabolism
Clinical traction / score 84
34 studies / 81 sources / 4 briefs / 8 articles
Inflammation and immune aging
Proof of concept / score 44
2 studies / 31 sources / 11 briefs / 2 articles
Stem cell and regeneration
Proof of concept / score 32
0 studies / 113 sources / 38 briefs / 0 articles
Brain aging and cognition
Clinical traction / score 78
27 studies / 43 sources / 3 briefs / 7 articles
Musculoskeletal resilience
Clinical traction / score 86
36 studies / 61 sources / 6 briefs / 9 articles
Microbiome and gut barrier
Early human evidence / score 73
9 studies / 11 sources / 0 briefs / 8 articles
- Human signal
- 67/100
- Clinical traction
- 30/100
- Frontier activity
- 56/100
- Evidence confidence
- 57/100
This progress map tracks whether aging-intervention claims are still mostly mechanism, have crossed into human translation, or are gaining clinical traction. It separates frontier activity from evidence maturity.
This map updates as Viral Vitalism adds studies, sources, briefs, claims, and timeline events. A row can gain velocity without gaining certainty. A frontier can be exciting without being clinically proven.
Map status
Counts are graph-derived. Published articles add coverage depth, while studies, sources, and claims form the evidence backbone.
VV Progress Map 1.0 / First public edition.
Generated 2026-07-08
- Rows
- 10
- Studies
- 127
- Sources
- 365
- Briefs
- 76
- Timeline events
- 13
- Articles
- 47
Progress matrix
All rows in one view
Dots fill from foundational science toward clinical traction. A dark frontier marker means active investigation is high, not that the lane is proven.
Epigenetic drift
Early human evidence / score 15
0 studies / 5 sources / 14 briefs / 0 articles
Cellular senescence
Proof of concept / score 41
2 studies / 2 sources / 0 briefs / 2 articles
Mitochondrial function
Early human evidence / score 65
6 studies / 7 sources / 0 briefs / 5 articles
Proteostasis and autophagy
Foundational science / score 53
11 studies / 11 sources / 0 briefs / 6 articles
Nutrient sensing and metabolism
Clinical traction / score 84
34 studies / 81 sources / 4 briefs / 8 articles
Inflammation and immune aging
Proof of concept / score 44
2 studies / 31 sources / 11 briefs / 2 articles
Stem cell and regeneration
Proof of concept / score 32
0 studies / 113 sources / 38 briefs / 0 articles
Brain aging and cognition
Clinical traction / score 78
27 studies / 43 sources / 3 briefs / 7 articles
Musculoskeletal resilience
Clinical traction / score 86
36 studies / 61 sources / 6 briefs / 9 articles
Microbiome and gut barrier
Early human evidence / score 73
9 studies / 11 sources / 0 briefs / 8 articles
Collective Progress Signal
Breadth is rising faster than certainty.
Aggregate scores summarize the current graph across all rows. They are not a medical recommendation or a single age-reversal score.
- Breadth
- 100/100
- 10 biology lanes, 365 source links.
- Maturity
- 42/100
- 127 study records matched across the map.
- Human translation signal
- 67/100
- Human-facing evidence with endpoint discipline. This is not an age-reversal score.
- Velocity
- 58/100
- 76 briefs and 13 timeline events matched.
- Clinical traction
- 30/100
- Share of rows currently reaching the clinical-traction maturity stage.
- Frontier activity
- 56/100
- Research movement kept separate from maturity and human proof.
- Evidence confidence
- 57/100
- Composite confidence after source quality, safety boundaries, and bias penalties.
- Coverage depth
- 54/100
- Broader human-facing coverage and context, not direct evidence maturity.
Velocity vs certainty
Fast-moving lanes are not always mature lanes.
X shows confidence. Y shows the higher of update velocity and frontier activity. The upper-left field is easiest to overread as hype.
Field-positioning view of 10 age-reversal research lanes. It is not a clinical ranking. Confidence is horizontal; the higher of update velocity and frontier activity is vertical.
Affected: relationship classification, update velocity, frontier activity
Interactive visualization
- Hype frontierActivity is moving faster than confidence. This is easiest to overread and is not a medical conclusion.
- Strong and movingConfidence and research activity are both above the field midpoint; this is not a treatment recommendation.
- Background biologyConfidence and current activity are both below the field midpoint; this can still be useful context.
- Established but slowerConfidence is above the midpoint while current research activity is lower; this does not imply clinical benefit.
Select a point to inspect its scores. Opening a row always requires the explicit link in this panel or the data table.
View data table
| Lane | Stage | Derived stage | Confidence | Update velocity | Frontier activity | Plotted Y | Plotted Y meaning | Evidence purity | Direct | Adjacent | Background | Sparse | Low-confidence broad matches | Frontier band | Stage explanation | Move-up explanation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brain aging and cognition | clinical-traction | clinical-traction | 78 | 70 | 50 | 70 | Higher of update velocity and frontier activity. | 100 | 105 | 0 | 0 | No | No | moderate | Clinical traction from 27 study records, 43 active source records, 3 rapid briefs, and 0 timeline events. Evidence maturity is 78/100, human translation signal is 75/100, and frontier activity is moderate (50/100). Frontier activity means research movement, not settled human proof. | Current bottleneck: stronger replication and longer follow-up would improve confidence. |
| Cellular senescence | proof-of-concept | proof-of-concept | 41 | 33 | 5 | 33 | Higher of update velocity and frontier activity. | 78 | 7 | 2 | 0 | No | No | low | Proof of concept from 2 study records, 2 active source records, 0 rapid briefs, and 0 timeline events. Evidence maturity is 15/100, human translation signal is 62/100, and frontier activity is low (5/100). Frontier activity means research movement, not settled human proof. Editorial placement shown publicly: Proof of concept. Graph-derived stage: Proof of concept. Override note: Senescence is a foundational aging-biology lane, but current VV graph support is still mostly mechanism and adjacent inflammation evidence. | Current bottleneck: evidence maturity, safety boundaries. |
| Epigenetic drift | early-human-evidence | proof-of-concept | 15 | 60 | 100 | 100 | Higher of update velocity and frontier activity. | 21 | 4 | 15 | 0 | No | No | extreme | Proof of concept from 0 study records, 5 active source records, 14 rapid briefs, and 0 timeline events. Evidence maturity is 0/100, human translation signal is 36/100, and frontier activity is extreme (100/100). Frontier activity means research movement, not settled human proof. Editorial placement shown publicly: Early human evidence. Graph-derived stage: Proof of concept. Override note: The current graph has live regenerative-medicine and early human translation signals, but not enough mature functional outcome evidence to call this clinical traction. | Current bottleneck: evidence maturity, human age-reversal translation, safety boundaries. |
| Inflammation and immune aging | proof-of-concept | proof-of-concept | 44 | 76 | 55 | 76 | Higher of update velocity and frontier activity. | 96 | 47 | 2 | 0 | No | No | moderate | Proof of concept from 2 study records, 31 active source records, 11 rapid briefs, and 0 timeline events. Evidence maturity is 15/100, human translation signal is 62/100, and frontier activity is moderate (55/100). Frontier activity means research movement, not settled human proof. | Current bottleneck: evidence maturity. |
| Microbiome and gut barrier | early-human-evidence | early-human-evidence | 73 | 40 | 10 | 40 | Higher of update velocity and frontier activity. | 100 | 45 | 0 | 0 | No | No | low | Early human evidence from 9 study records, 11 active source records, 0 rapid briefs, and 0 timeline events. Evidence maturity is 63/100, human translation signal is 87/100, and frontier activity is low (10/100). Frontier activity means research movement, not settled human proof. | Current bottleneck: safety boundaries. |
| Mitochondrial function | early-human-evidence | early-human-evidence | 65 | 40 | 10 | 40 | Higher of update velocity and frontier activity. | 84 | 16 | 3 | 0 | No | No | low | Early human evidence from 6 study records, 7 active source records, 0 rapid briefs, and 0 timeline events. Evidence maturity is 57/100, human translation signal is 63/100, and frontier activity is low (10/100). Frontier activity means research movement, not settled human proof. | Current bottleneck: safety boundaries. |
| Musculoskeletal resilience | clinical-traction | clinical-traction | 86 | 82 | 100 | 100 | Higher of update velocity and frontier activity. | 84 | 124 | 24 | 0 | No | No | extreme | Clinical traction from 36 study records, 61 active source records, 6 rapid briefs, and 6 timeline events. Evidence maturity is 86/100, human translation signal is 85/100, and frontier activity is extreme (100/100). Frontier activity means research movement, not settled human proof. | Current bottleneck: stronger replication and longer follow-up would improve confidence. |
| Nutrient sensing and metabolism | clinical-traction | clinical-traction | 84 | 83 | 100 | 100 | Higher of update velocity and frontier activity. | 100 | 172 | 0 | 0 | No | No | extreme | Clinical traction from 34 study records, 81 active source records, 4 rapid briefs, and 7 timeline events. Evidence maturity is 87/100, human translation signal is 76/100, and frontier activity is extreme (100/100). Frontier activity means research movement, not settled human proof. | Current bottleneck: stronger replication and longer follow-up would improve confidence. |
| Proteostasis and autophagy | foundational-science | proof-of-concept | 53 | 40 | 25 | 40 | Higher of update velocity and frontier activity. | 62 | 23 | 14 | 0 | No | No | low | Proof of concept from 11 study records, 11 active source records, 0 rapid briefs, and 0 timeline events. Evidence maturity is 15/100, human translation signal is 62/100, and frontier activity is low (25/100). Frontier activity means research movement, not settled human proof. Editorial placement shown publicly: Foundational science. Graph-derived stage: Proof of concept. Override note: The current graph has adjacent nutrition and exercise coverage, but explicit autophagy/proteostasis records are not yet deep enough for a higher data-derived stage. | Current bottleneck: evidence maturity, safety boundaries. |
| Stem cell and regeneration | proof-of-concept | proof-of-concept | 32 | 60 | 100 | 100 | Higher of update velocity and frontier activity. | 100 | 151 | 0 | 0 | No | No | extreme | Proof of concept from 0 study records, 113 active source records, 38 rapid briefs, and 0 timeline events. Evidence maturity is 0/100, human translation signal is 60/100, and frontier activity is extreme (100/100). Frontier activity means research movement, not settled human proof. | Current bottleneck: evidence maturity. |
Sources and provenance (10)
context
- Brain aging and cognition evidence detailpublic review artifact · background
Open the public row for its complete evidence and scoring explanation.
- Cellular senescence evidence detailpublic review artifact · background
Open the public row for its complete evidence and scoring explanation.
- Epigenetic drift evidence detailpublic review artifact · background
Open the public row for its complete evidence and scoring explanation.
- Inflammation and immune aging evidence detailpublic review artifact · background
Open the public row for its complete evidence and scoring explanation.
- Microbiome and gut barrier evidence detailpublic review artifact · background
Open the public row for its complete evidence and scoring explanation.
- Mitochondrial function evidence detailpublic review artifact · background
Open the public row for its complete evidence and scoring explanation.
- Musculoskeletal resilience evidence detailpublic review artifact · background
Open the public row for its complete evidence and scoring explanation.
- Nutrient sensing and metabolism evidence detailpublic review artifact · background
Open the public row for its complete evidence and scoring explanation.
- Proteostasis and autophagy evidence detailpublic review artifact · background
Open the public row for its complete evidence and scoring explanation.
- Stem cell and regeneration evidence detailpublic review artifact · background
Open the public row for its complete evidence and scoring explanation.
Latest map movement
Newest evidence events across the rows
Briefs add velocity. Studies, sources, claims, and timeline records carry the stronger maturity signal.
How to read this map
Stage
The current maturity lane for the row.
Score
A graph-derived signal from evidence maturity, source quality, translation, safety, and velocity.
Frontier
Active investigation, not proof.
Briefs
Movement and velocity, not validation by themselves.
Evidence backbone
Studies, sources, and claims carry stronger maturity weight.
Methodology
What changes the map
What moves a row up
Evidence-bearing studies, high-quality source records, direct research timeline events, human outcomes, replication, and stronger safety boundaries.
What does not move a row up
Published articles, generic topic overlap, broad longevity language, or brief volume without stronger underlying evidence.
Why frontier is separate
Frontier activity tracks research movement, regulatory activity, and experimental programs. It is not settled human proof.
Why briefs affect velocity
Briefs are useful for recency and monitoring. They raise update velocity more than maturity unless their linked studies or sources support the claim.
Why biomarkers are penalized
Biomarker-only evidence can be useful but often fails to prove functional or clinical benefit, so it cannot carry age-reversal claims alone.
Why human signal is bounded
The human translation signal is an endpoint-quality signal, not an age-reversal score or medical recommendation.
Evidence discipline
Not all pathways are equally validated. The point is not one magic bullet, but the expanding breadth of aging interventions under active investigation.